Skip to main content

Table 1 Correlation between clinicopathological features and plakoglobin and E-cadherin expression in 121 patients with breast cancer

From: Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer

Parameters

plakoglobin

p value

E-cadherin

p value

High (n = 21)

Low (n = 100)

High (n = 71)

Low (n = 50)

HR and HER2 status

 

 TNBC

4 (19.0%)

35 (35.0%)

0.203

15 (21.1%)

24 (48.0%)

0.003

 non-TNBC

17 (81.0%)

65 (65.0%)

56 (78.9%)

26 (52.0%)

HER2 status

 negative

16 (76.2%)

70 (70.0%)

 

47 (66.2%)

39 (78.0%)

0.222

 positive

5 (23.8%)

30 (30.0%)

0.792

24 (33.8%)

11 (22.0%)

Age at operation

  ≤ 56

12 (57.1%)

45 (45.0%)

0.344

34 (47.9%)

23 (46.0%)

0.855

  > 56

9 (42.9%)

55 (55.0%)

37 (52.1%)

27 (54.0%)

Menopause

 Negative

10 (47.6%)

38 (38.0%)

0.466

28 (39.4%)

20 (40.0%)

0.950

 Positive

11 (52.4%)

62 (62.0%)

43 (60.6%)

30 (60.0%)

Tumor size

  ≤ 2 cm

2 (9.5%)

15 (15.0%)

0.734

9 (12.7%)

8 (16.0%)

0.607

  > 2 cm

19 (90.5%)

85 (85.0%)

62 (87.3%)

42 (84.0%)

Lymph node status

 Negative

8 (38.1%)

27 (27.0%)

0.304

23 (32.4%)

12 (24.0%)

0.416

 Positive

13 (61.9%)

73 (73.0%)

48 (67.6%)

38 (76.0%)

Nuclear grade

 1, 2

16 (76.2%)

78 (78.0%)

0.857

54 (76.1%)

40 (80.0%)

0.663

 3

5 (23.8%)

22 (22.0%)

17 (23.9%)

10 (20.0%)

Ki67

  ≤ 14%

6 (28.6%)

45 (45.0%)

0.225

30 (42.3%)

21 (42.0%)

0.978

  > 14%

15 (71.4%)

55 (55.0%)

41 (57.7%)

29 (58.0%)

Pathological response

 pCR

7 (33.3%)

41 (41.0%)

0.627

39 (54.9%)

34 (68.0%)

0.187

 non-pCR

14 (66.7%)

59 (59.0%)

32 (45.1%)

16 (32.0%)

Plakoglobin

 Low

Not

Not

 

54 (76.1%)

46 (92.0%)

0.023

 High

determined

determined

17 (23.9%)

4 (8.0%)

E-cadherin

 Negative

4 (19.0%)

46 (46.0%)

0.023

Not

Not

 

 Positive

17 (81.0%)

54 (54.0%)

determined

determined

  1. HER2 human epidermal growth factor receptor 2; HR hormone receptor; pCR pathological complete response; TNBC triple-negative breast cancer